Weight Gain  >>  Symlin (pramlintide)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Symlin (pramlintide) / AstraZeneca
NCT00505882: Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

Withdrawn
4
0
US
Pramlintide, Symlin, Glargine, Lispro, Aspart
University of Texas Southwestern Medical Center
Type 1 Diabetes
12/08
12/08
NCT00690235: Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

Completed
4
33
US
Pramlintide, Amylin, Placebo, sterile saline
University of Texas Southwestern Medical Center, Amylin Pharmaceuticals, LLC.
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
08/11
08/11

Download Options